FDA approves first gene therapy for Sanfilippo syndrome type A
Go back to FDA approves first gene therapy for Sanfilippo syndrome type A| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 15.65 -0.3 (1.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.95 | 52 Week High | $117.12 | |||
| Open | $15.92 | 52 Week Low | $46.52 | |||
| Day High | $15.94 | P/E | N/A | |||
| Day Low | $15.49 | EPS | $-1.97 | |||
| Volume | 1,788,779 | |||||



